Sharekhan

Akums Drugs and Pharmaceuticals Ltd

Thu 13/03/2025,15:57:44 | NSE : AKUMS

₹ 510.25-6.95 (-1.34%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 515.00

Previous Close

₹ 517.20

Volume

133626

Mkt Cap ( Rs. Cr)

₹8031.03

High

₹ 520.65

Low

₹ 506.40

52 Week High

₹ 1175.90

52 Week Low

₹ 432.60

Book Value Per Share

₹ 180.08

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

69.57%

Hold

17.39%

Sell

13.04%

69.57%

23 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Mar 2025, 6:06PM Schedule of Analyst and Investor Meet
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Mar 2025, 12:25PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Mar 2025, 12:29PM Schedule of Analyst and Investor Meet
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Mar 2025, 5:47PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Mar 2025, 5:51PM Intimation of Schedule of the Analysts/Investor Meet (group meet).
  • Akums Drugs & Pharma - Copy of Newspaper Publication

    15 Feb 2025, 12:17PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
  • Akums Drugs & Pharma - General Updates

    14 Feb 2025, 3:27PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about General Updates
  • Akums Drugs & Pharma - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure

    14 Feb 2025, 3:22PM Grant of Patent.
  • Akums Drugs & Pharma - Shareholders meeting

    14 Feb 2025, 12:59PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
  • Akums Drugs & Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    14 Feb 2025, 12:49PM Intimation of Postal Ballot Notice
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Feb 2025, 6:34PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet and Presentation
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    11 Feb 2025, 6:30PM Investor Meet on 14th February, 2025.
  • Akums Drugs & Pharma - Monitoring Agency Report

    11 Feb 2025, 12:33PM Monitoring Agency Report Q3 FY25
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Feb 2025, 12:31PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    11 Feb 2025, 12:21PM Monitoring Agency Report Q3 FY25
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    11 Feb 2025, 12:18PM Transcript of Earning call held for limited reviewed un-audited financial results of Q3 FY25
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Feb 2025, 6:53PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Link of recordings
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 Feb 2025, 6:49PM Audio Recording of Investor Call for Q3 FY 2025
  • Akums Drugs & Pharma - Statement Of Deviation.

    7 Feb 2025, 3:56PM Statement of Deviation.
  • Akums Drugs & Pharma - Integrated Filing (Financial)

    7 Feb 2025, 3:53PM Integrated Filing
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    7 Feb 2025, 3:48PM Investor Presentation.
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    7 Feb 2025, 3:46PM Press Release
  • Akums Drugs & Pharma - Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2024.

    7 Feb 2025, 3:42PM Un-audited Financial Results for the quarter and nine months ended December 31, 2024.
  • Akums Drugs & Pharma - Copy of Newspaper Publication

    7 Feb 2025, 1:16PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
  • Akums Drugs & Pharma - Integrated Filing- Financial

    6 Feb 2025, 7:04PM Integrated Filing
  • Akums Drugs & Pharma - Statement of deviation(s) or variation(s) under Reg. 32

    6 Feb 2025, 6:32PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
  • Akums Drugs & Pharma - Investor Presentation

    6 Feb 2025, 6:29PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
  • Akums Drugs & Pharma - Statement Of Deviation

    6 Feb 2025, 6:25PM Statement of Deviation
  • Akums Drugs & Pharma - Press Release

    6 Feb 2025, 6:23PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 06, 2025, titled ""Press Release for Decemb
  • Akums Drugs & Pharma - Integrated Filing (Financial)

    6 Feb 2025, 6:23PM Integrated Filing of Results
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

    6 Feb 2025, 6:17PM Investor Presentation
  • Akums Drugs & Pharma - Financial Result Updates

    6 Feb 2025, 6:13PM Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Akums Drugs & Pharma Q3 net profit jumps 40.32% at Rs 41.17 cr

    6 Feb 2025, 6:12PM The company reported standalone net profit of Rs 41.17 crore for the quarter ended December 31, 2024 as compared to Rs 29.34 crore in the same period
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Feb 2025, 6:11PM Press Release
  • Akums Drugs & Pharma - Outcome of Board Meeting

    6 Feb 2025, 6:10PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 06, 2025.
  • Akums Drugs & Pharma - Outcome Of Board Meeting Held On 06Th February, 2025.

    6 Feb 2025, 6:06PM In terms of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, th
  • Akums Drugs & Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th February, 2025

    6 Feb 2025, 5:58PM Respected Sir/Madam,\r\n\r\nIn terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requireme
  • Akums Drugs & Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    5 Feb 2025, 3:09PM AKUMS DRUGS AND PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Sh
  • Akums Drugs & Pharma - Updates

    5 Feb 2025, 3:08PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Cessation of Mr. Nand Lal Kalra (DIN: 05268554) Independent director of t
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Cessation

    5 Feb 2025, 3:00PM Cessation of Mr. Nand Lal Kalra (DIN: 05268554) Independent director of the company w.e.f 05.02.2025 due to attain the age of 75 years.
  • Akums Drugs & Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Feb 2025, 11:41AM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Feb 2025, 11:43AM Schedule of Analyst / Investor Meet
  • Akums Drugs & Pharma - Board Meeting Intimation

    1 Feb 2025, 3:24PM AKUMS DRUGS AND PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Feb-2025 to inter-alia consider and approve the
  • Akums Drugs & Pharma - Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months

    1 Feb 2025, 3:18PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 ,inter alia,
  • Akums Drugs & Pharma - Update On Income Tax Search

    23 Jan 2025, 6:27PM Update on Income Tax Search
  • Akums Drugs & Pharma - Updates

    23 Jan 2025, 5:57PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Update on Income Tax Search'.
  • Akums Drugs & Pharma - Updates

    22 Jan 2025, 11:01AM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Income Tax Search'.
  • Akums Drugs & Pharma - Income Tax Search

    22 Jan 2025, 10:58AM Income Tax Search
  • Akums Drugs & Pharma - Updates

    2 Jan 2025, 2:21PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Change of name of RTA'.
  • Akums Drugs & Pharma - Change Of Name Of RTA

    2 Jan 2025, 2:23PM Change of Name of RTA
  • Akums Drugs & Pharma - Trading Window-XBRL

    28 Dec 2024, 12:36PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window
  • Akums Drugs & Pharma - Trading Window

    28 Dec 2024, 12:30PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs & Pharma - Agreements,Contracts,Arrangements,MOU-XBRL

    27 Dec 2024, 11:46AM AKUMS DRUGS AND PHARMACEUTICALS LIMITED has informed the Exchange regarding Long-Term CDMO Agreement with a Leading Global Pharma Company and supply i
  • Akums Drugs & Pharma - Agreements

    24 Dec 2024, 12:30PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Agreements Akums has entered into an agreement with one of Leading Global Phar
  • Akums Drugs & Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

    24 Dec 2024, 12:37PM Akums has entered into an agreement with one of leading global pharma company (\Company\) for manufacture and supply of selected pharmaceuticals formu
  • Akums Drugs & Pharma - Shareholders meeting

    17 Dec 2024, 4:59PM Akums Drugs and Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot with scrutinizers report
  • Akums Drugs & Pharma - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    17 Dec 2024, 4:46PM Voting Results of Postal Ballot along with the Scrutinizers Report

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-24
Assets 370.164
Liabilities 370.164
Equity 28.613
Gross Profit -126.658
Net Profit -165.451
Cash From Operating Activities 247.907
NPM(%) -11.45
Revenue 1444.119
Expenses 1570.777
ROE(%) -5.83

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 291.38 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 1061.76 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 547.27 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 1001.14 -239.30 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited

Read More

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ

The current price of Akums Drugs and Pharmaceuticals Ltd is ₹ 510.25.

The 52-week high for Akums Drugs and Pharmaceuticals Ltd is ₹ 520.65 and the 52-week low is ₹ 506.40.

The market capitalization of Akums Drugs and Pharmaceuticals Ltd is currently ₹ 8031.03. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Akums Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Akums Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Akums Drugs and Pharmaceuticals Ltd shares.

The CEO of Akums Drugs and Pharmaceuticals Ltd is Mr.Sanjeev Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT